Liver regeneration in donors and adult recipients after living donor liver transplantation

Junko Haga, Motohide Shimazu, Go Wakabayashi, Minoru Tanabe, Shigeyuki Kawachi, Yasushi Fuchimoto, Ken Hoshino, Yasuhide Morikawa, Masaki Kitajima, Yuko Kitagawa – 24 November 2008 – In living donor liver transplantation, the safety of the donor operation is the highest priority. The introduction of the right lobe graft was late because of concerns about donor safety. We investigated donor liver regeneration by the types of resected segments as well as recipients to assess that appropriate regeneration was occurring.

Report of the Paris consensus meeting on expanded criteria donors in liver transplantation

François Durand, John F. Renz, Barbara Alkofer, Patrizia Burra, Pierre‐Alain Clavien, Robert J. Porte, Richard B. Freeman, Jacques Belghiti – 24 November 2008 – Because of organ shortage and a constant imbalance between available organs and candidates for liver transplantation, expanded criteria donors are needed. Experience shows that there are wide variations in the definitions, selection criteria, and use of expanded criteria donors according to different geographic areas and different centers. Overall, selection criteria for donors have tended to be relaxed in recent years.

Biliary reconstruction for infantile living donor liver transplantation: Roux‐en‐Y hepaticojejunostomy or duct‐to‐duct choledochocholedochostomy?

Yasumasa Shirouzu, Hideaki Okajima, Satsuki Ogata, Yuki Ohya, Yukika Tsukamoto, Hidekazu Yamamoto, Takayuki Takeichi, Lee Kwang‐Jong, Katsuhiro Asonuma, Yukihiro Inomata – 24 November 2008 – Hepaticojejunostomy is a standard biliary reconstruction method for infantile living donor liver transplantation (LDLT), but choledochocholedochostomy for infants is not generally accepted yet. Ten pediatric recipients weighing no more than 10 kg underwent duct‐to‐duct choledochocholedochostomy (DD) for biliary reconstruction for LDLT.

Hydroxyethyl starch–based preservation solutions enhance gene therapy vector delivery under hypothermic conditions

Scot D. Henry, Pascal van der Wegen, Herold J. Metselaar, Bob J. Scholte, Hugo W. Tilanus, Luc J. W. van der Laan – 24 November 2008 – Isolated liver perfusion offers a unique prospect for safe, effective targeting of gene therapies that can be directed against allograft rejection or recurrent diseases such as reinfection by hepatitis C virus (HCV). We aimed to examine the effect of organ preservation solutions on vector‐based gene therapy delivery under hypothermic conditions.

Impact of immunosuppression without steroids on rejection and hepatitis C virus evolution after liver transplantation: Results of a prospective randomized study

Laura Lladó, Joan Fabregat, Jose Castellote, Emilio Ramos, Xavier Xiol, Jaume Torras, Teresa Serrano, Carme Baliellas, Joan Figueras, Agustin Garcia‐Gil, Antoni Rafecas – 24 November 2008 – The purpose of this study was to evaluate the influence of a steroid‐free immunosuppression on hepatitis C virus (HCV) recurrence. A total of 198 liver transplantation (LT) patients were randomized to receive immunosuppression with basiliximab and cyclosporine, either with prednisone (steroid [St] group) or without prednisone (no steroids [NoSt] group).

Subscribe to